500LBA LBA Orals: Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
Titel:
500LBA LBA Orals: Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
Auteur:
Tran, B. Boni, A. Hansen, A. Boni, V. Mantia, C. Yu, E. Weickhardt, A. Robert, M. Gupta, S. Necchi, A. Morales-Barrera, R. Hoimes, C. Berlin, J. Iyer, G. Millward, M. Burn, T. Lihou, C. Gammon, G. Rosenberg, J. Loriot, Y.